International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
Identifieur interne : 001898 ( Istex/Corpus ); précédent : 001897; suivant : 001899International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
Auteurs : Olivia Pagani ; Elbieta Senkus ; William Wood ; Marco Colleoni ; Tanja Cufer ; Stella Kyriakides ; Alberto Costa ; Eric P. Winer ; Fatima CardosoSource :
- Journal of the National Cancer Institute [ 0027-8874 ] ; 2010.
Abstract
A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detectable metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and regional chemotherapy. The European School of OncologyMetastatic Breast Cancer Task Force addressed the management of these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospective series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of systemic therapies, possibly in combination with optimal local treatment.
Url:
DOI: 10.1093/jnci/djq029
Links to Exploration step
ISTEX:57938F7FCAFED132CBF23F251E3828D8422189D8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</title><author><name sortKey="Pagani, Olivia" sort="Pagani, Olivia" uniqKey="Pagani O" first="Olivia" last="Pagani">Olivia Pagani</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Senkus, Elbieta" sort="Senkus, Elbieta" uniqKey="Senkus E" first="Elbieta" last="Senkus">Elbieta Senkus</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Wood, William" sort="Wood, William" uniqKey="Wood W" first="William" last="Wood">William Wood</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Colleoni, Marco" sort="Colleoni, Marco" uniqKey="Colleoni M" first="Marco" last="Colleoni">Marco Colleoni</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Cufer, Tanja" sort="Cufer, Tanja" uniqKey="Cufer T" first="Tanja" last="Cufer">Tanja Cufer</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Kyriakides, Stella" sort="Kyriakides, Stella" uniqKey="Kyriakides S" first="Stella" last="Kyriakides">Stella Kyriakides</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Costa, Alberto" sort="Costa, Alberto" uniqKey="Costa A" first="Alberto" last="Costa">Alberto Costa</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Winer, Eric P" sort="Winer, Eric P" uniqKey="Winer E" first="Eric P." last="Winer">Eric P. Winer</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Cardoso, Fatima" sort="Cardoso, Fatima" uniqKey="Cardoso F" first="Fatima" last="Cardoso">Fatima Cardoso</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: fatima.cardoso@bordet.be</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:57938F7FCAFED132CBF23F251E3828D8422189D8</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1093/jnci/djq029</idno><idno type="url">https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001898</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</title><author><name sortKey="Pagani, Olivia" sort="Pagani, Olivia" uniqKey="Pagani O" first="Olivia" last="Pagani">Olivia Pagani</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Senkus, Elbieta" sort="Senkus, Elbieta" uniqKey="Senkus E" first="Elbieta" last="Senkus">Elbieta Senkus</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Wood, William" sort="Wood, William" uniqKey="Wood W" first="William" last="Wood">William Wood</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Colleoni, Marco" sort="Colleoni, Marco" uniqKey="Colleoni M" first="Marco" last="Colleoni">Marco Colleoni</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Cufer, Tanja" sort="Cufer, Tanja" uniqKey="Cufer T" first="Tanja" last="Cufer">Tanja Cufer</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Kyriakides, Stella" sort="Kyriakides, Stella" uniqKey="Kyriakides S" first="Stella" last="Kyriakides">Stella Kyriakides</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Costa, Alberto" sort="Costa, Alberto" uniqKey="Costa A" first="Alberto" last="Costa">Alberto Costa</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Winer, Eric P" sort="Winer, Eric P" uniqKey="Winer E" first="Eric P." last="Winer">Eric P. Winer</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation></author><author><name sortKey="Cardoso, Fatima" sort="Cardoso, Fatima" uniqKey="Cardoso F" first="Fatima" last="Cardoso">Fatima Cardoso</name><affiliation><mods:affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: fatima.cardoso@bordet.be</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the National Cancer Institute</title><idno type="ISSN">0027-8874</idno><idno type="eISSN">1460-2105</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2010">2010</date><biblScope unit="volume">102</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="456">456</biblScope><biblScope unit="page" to="463">463</biblScope></imprint><idno type="ISSN">0027-8874</idno></series><idno type="istex">57938F7FCAFED132CBF23F251E3828D8422189D8</idno><idno type="DOI">10.1093/jnci/djq029</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0027-8874</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detectable metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and regional chemotherapy. The European School of OncologyMetastatic Breast Cancer Task Force addressed the management of these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospective series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of systemic therapies, possibly in combination with optimal local treatment.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Olivia Pagani</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>Elbieta Senkus</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>William Wood</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>Marco Colleoni</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>Tanja Cufer</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>Stella Kyriakides</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>Alberto Costa</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>Eric P. Winer</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string></affiliations></json:item><json:item><name>Fatima Cardoso</name><affiliations><json:string>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</json:string><json:string>E-mail: fatima.cardoso@bordet.be</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>COMMENTARY</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detectable metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and regional chemotherapy. The European School of OncologyMetastatic Breast Cancer Task Force addressed the management of these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospective series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of systemic therapies, possibly in combination with optimal local treatment.</abstract><qualityIndicators><score>8.368</score><pdfVersion>1.4</pdfVersion><pdfPageSize>594 x 783 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1700</abstractCharCount><pdfWordCount>6999</pdfWordCount><pdfCharCount>46031</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>239</abstractWordCount></qualityIndicators><title>International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</title><genre><json:string>research-article</json:string></genre><host><volume>102</volume><publisherId><json:string>jnci</json:string></publisherId><pages><last>463</last><first>456</first></pages><issn><json:string>0027-8874</json:string></issn><issue>7</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2105</json:string></eissn><title>Journal of the National Cancer Institute</title></host><categories><wos><json:string>ONCOLOGY</json:string></wos></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1093/jnci/djq029</json:string></doi><id>57938F7FCAFED132CBF23F251E3828D8422189D8</id><score>0.21498199</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability status="free"><p>Open Access</p></availability><date>2010</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</title><author xml:id="author-1"><persName><forename type="first">Olivia</forename><surname>Pagani</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-2"><persName><forename type="first">Elbieta</forename><surname>Senkus</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-3"><persName><forename type="first">William</forename><surname>Wood</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-4"><persName><forename type="first">Marco</forename><surname>Colleoni</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-5"><persName><forename type="first">Tanja</forename><surname>Cufer</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-6"><persName><forename type="first">Stella</forename><surname>Kyriakides</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-7"><persName><forename type="first">Alberto</forename><surname>Costa</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-8"><persName><forename type="first">Eric P.</forename><surname>Winer</surname></persName><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author><author xml:id="author-9" corresp="yes"><persName><forename type="first">Fatima</forename><surname>Cardoso</surname></persName><email>fatima.cardoso@bordet.be</email><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation></author></analytic><monogr><title level="j">Journal of the National Cancer Institute</title><idno type="pISSN">0027-8874</idno><idno type="eISSN">1460-2105</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2010"></date><biblScope unit="volume">102</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="456">456</biblScope><biblScope unit="page" to="463">463</biblScope></imprint></monogr><idno type="istex">57938F7FCAFED132CBF23F251E3828D8422189D8</idno><idno type="DOI">10.1093/jnci/djq029</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detectable metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and regional chemotherapy. The European School of OncologyMetastatic Breast Cancer Task Force addressed the management of these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospective series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of systemic therapies, possibly in combination with optimal local treatment.</p></abstract><textClass><keywords scheme="keyword"><list><item><term>COMMENTARY</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-10-14">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">jnci</journal-id><journal-id journal-id-type="publisher-id">jnci</journal-id><journal-title>Journal of the National Cancer Institute</journal-title><issn pub-type="epub">1460-2105</issn><issn pub-type="ppub">0027-8874</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/jnci/djq029</article-id><article-categories><subj-group><subject>COMMENTARY</subject></subj-group></article-categories><title-group><article-title>International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pagani</surname><given-names>Olivia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Senkus</surname><given-names>Elżbieta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>William</given-names></name></contrib><contrib contrib-type="author"><name><surname>Colleoni</surname><given-names>Marco</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cufer</surname><given-names>Tanja</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kyriakides</surname><given-names>Stella</given-names></name></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Alberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Winer</surname><given-names>Eric P.</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cardoso</surname><given-names>Fatima</given-names></name></contrib><contrib contrib-type="author"><on-behalf-of>on behalf of the ESO–MBC Task Force</on-behalf-of></contrib></contrib-group><aff><bold>Affiliations of authors:</bold> Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</aff><author-notes><corresp><bold>Correspondence to:</bold> Fatima Cardoso, MD, Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 125, 1000 Brussels, Belgium (e-mail: <email>fatima.cardoso@bordet.be</email>).</corresp></author-notes><pub-date pub-type="epub-ppub"><day>7</day><month>4</month><year>2010</year></pub-date><volume>102</volume><issue>7</issue><fpage>456</fpage><lpage>463</lpage><history><date date-type="rev-recd"><day>20</day><month>1</month><year>2010</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>© The Author 2010. Published by Oxford University Press.</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detectable metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and regional chemotherapy. The European School of Oncology–Metastatic Breast Cancer Task Force addressed the management of these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospective series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of systemic therapies, possibly in combination with optimal local treatment.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?</title></titleInfo><name type="personal"><namePart type="given">Olivia</namePart><namePart type="family">Pagani</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elbieta</namePart><namePart type="family">Senkus</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William</namePart><namePart type="family">Wood</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marco</namePart><namePart type="family">Colleoni</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tanja</namePart><namePart type="family">Cufer</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stella</namePart><namePart type="family">Kyriakides</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alberto</namePart><namePart type="family">Costa</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eric P.</namePart><namePart type="family">Winer</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Fatima</namePart><namePart type="family">Cardoso</namePart><affiliation>Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)</affiliation><affiliation>E-mail: fatima.cardoso@bordet.be</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><topic>COMMENTARY</topic></subject><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2010</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detectable metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and regional chemotherapy. The European School of OncologyMetastatic Breast Cancer Task Force addressed the management of these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospective series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of systemic therapies, possibly in combination with optimal local treatment.</abstract><relatedItem type="host"><titleInfo><title>Journal of the National Cancer Institute</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0027-8874</identifier><identifier type="eISSN">1460-2105</identifier><identifier type="PublisherID">jnci</identifier><identifier type="PublisherID-hwp">jnci</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>456</start><end>463</end></extent></part></relatedItem><identifier type="istex">57938F7FCAFED132CBF23F251E3828D8422189D8</identifier><identifier type="DOI">10.1093/jnci/djq029</identifier><accessCondition type="use and reproduction" contentType="open-access">This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/covers/tiff</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/annexes/pdf</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">ONCOLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI><json:item><type>refBibs</type><uri>https://api.istex.fr/document/57938F7FCAFED132CBF23F251E3828D8422189D8/enrichments/refBibs</uri></json:item></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001898 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001898 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:57938F7FCAFED132CBF23F251E3828D8422189D8
|texte= International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
}}
| This area was generated with Dilib version V0.6.25. |  |